Business
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31% CR/CRh rate observed at the highest target dose tested to date; initial dose escalation results in 45 patients demonstrate a favorable safety profile across all doses assessed CLN-049 recently granted Fast Track designation by the U.S. FDA Company to host in-person event on Monday, December 8, at
About this update from Cullinan Therapeutics, Inc.
[{"type":"image","alt":"Cullinan Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cullinan Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":156,"url":"https://media.zenfs.com/en/globenewswire.com/4f6a15e3a48555fdf49ef58383e73f66"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TGTCiuVP_5igE.Nd1ysn1g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4f6a15e3a48555fdf49ef58383e73f66","width":300,"height":156}},"lazy":false},{"type":"text","content":"CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML","length":197,"tagName":"p"},{"type":"text","content":"31% CR/CRh rate observed at the highest target dose tested to date; initial dose escalation results in 45 patients demonstrate a favorable safety profile across all doses assessed","length":179,"tagName":"p"},{"type":"text","content":"CLN-049 recently granted Fast Track designation by the U.S. FDA","length":63,"tagName":"p"},{"type":"text","content":"Company to host in-person event on Monday, December 8, at 8:00 p.m. ET","length":70,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today shared updated clinical data from its Phase 1 study of CLN-049, a novel, investigational FLT3xCD3 bispecific T cell engager, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These data will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9, as an oral presentation on Monday, December 8, at 10:45 a.m. ET.","length":686,"tagName":"p"},{"type":"text","content":"“These promising clinical data, including multiple complete responses and encouraging initial data for response durability, demonstrate the potential for CLN-049 to expand treatment options for a broad population of people with AML, including patients with TP53-mutated AML who currently face a particularly poor prognosis,” said Jeffrey Jones, MD, MB...